In reference to the article ?Chromosome copies confer resistance? by Melissa Lee Phillips, we wish to bring to your attention that the first report on aneuploidy of a specific chromosome conferring resistance to fluconazole in the human opportunistic pathogen Candida albicans, was published by V. Perepnikhatka, F. J. Fisher, M. Niimi, R. A. Baker, R. D. Cannon, Y.-K. Wang, F. Sherman and E. Rustchenko (Specific chromosomal alterations in fluconazole-resistant mutants of Candida albicans. J. Bacteriol. 181, 4041-4049 ). In this paper, we established for the first time that either diminution of chromosome 4 or a combination of chromosome 4 diminution and chromosome 3 duplication conveys the resistance. This control represented a novel mechanism, which did not involve either the gene ERG11, a target of fluconazole, or the genes for cellular pumps that reside on chromosome 5. Our publication was part of a more general effort being used to demonstrate that C. albicans uses changes in copy number of specific chromosomes to survive in specific adverse environments. Our results on C. albicans survival on a toxic sugar L-sorbose, non-utilized sugar D-arabinose, as well as toxic 5-fluoro-orotic acid and fluconazole, were presented in numerous experimental and review papers. In fact, Dr. J. Berman cited the paper by Perepnikhatka et al. in her review ?Candida albicans: a molecular revolution built on lessons from budding yeast? (J. Berman and P. E. Sudbery, 2002, Nature Reviews Genetics 3: 918-930), but failed to acknowledged our pioneering publication in her current paper. Although, our paper by Perepnikhatka et al. was not cited in "Aneuploidy and isochromosome formation in drug-resistant Candida albicans" (A. Selmecki, A. Forche, J. Berman, 2006, Science 313: 367-370), it is satisfying to know that another laboratory confirmed the relationship between aneuploidy and the resistance to fluconazole.